In vivo effects of pardoprunox (SLV308), a partial D₂/D₃ receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity.
Synapse (New York, N.Y.) • Vol. 65, Issue 10 • 2011
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
Experimental neurology • Vol. 226, Issue 2 • 2010
Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.
Movement disorders : official journal of the Movement Disorder Society • Vol. 25, Issue 6 • 2010
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology • Vol. 20, Issue 8 • 2010
